1. Home
  2. ZNTL

as 08-22-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Founded: 2014 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 105.8M IPO Year: 2020
Target Price: $8.46 AVG Volume (30 days): 768.8K
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.28 EPS Growth: N/A
52 Week Low/High: $1.01 - $5.44 Next Earning Date: 08-06-2025
Revenue: $26,865,000 Revenue Growth: -33.77%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

ZNTL Daily Stock ML Predictions

Share on Social Networks: